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Presbycusis (hearing loss that occurs with age) affects 30% of adults aged 65 to 74, yet hearing 
loss is rarely considered when developing novel treatment deliveries. For example, research 
shows that telepsychiatry improves depression symptoms among geriatric patients similarly to 
traditional forms of therapy, however, there is no literature on effectiveness of telepsychiatry in 
geriatrics with presbycusis. The objective of this study is to assess whether, compared to face-to-
face psychotherapy, telepsychiatry produces superior outcomes assessed by the Beck Depression 
Inventory II, among depressed geriatric patients suffering from presbycusis. We will conduct a 
randomized controlled trial among elderly individuals with depressive disorders and presbycusis 
who will be randomly allocated to 8 weekly, 60-minute manual sessions of Behavioral 
Activation Therapy for Depression either in the clinic or in the participants’ home, using 
telepsychiatry. This study will help guide future therapies directed towards the growing geriatric 







Chapter 1 – Introduction 
Background 
Telemedicine is the electronic transfer of medical and health information between distant 
sites and participants.1 It has seen tremendous growth in the information age and has been 
successfully applied across various fields of medicine.2-4 Technological advances that have made 
the relevant equipment less expensive and easier to use have stimulated so much interest and 
success in telemedicine that it is now a well-accepted method of diagnosis and treatment.5  
 Telepsychiatry—the delivery of healthcare and the exchange of healthcare information 
for the purposes of providing psychiatric services across distances6—has grown rapidly probably 
due to the easy adaptation of traditional talk therapy to delivery via telemedicine, specifically 
video-based telemedicine. Telepsychiatry review articles indicate that this form of medicine 
increases access to care, yields improved patient outcomes and leads to increased patient 
satisfaction.7  
 Many studies have examined the effectiveness, feasibility and acceptability of 
telepsychiatry, which has been successfully used in veterans with post-traumatic stress disorder,8 
Alzheimer’s dementia,9 and other mental health disorders.10 However, more research is needed 
on clinical outcomes of telepsychiatry treatment models.7  
 Telepsychiatry has also been studied in various patient populations, but the geriatric 
population will likely benefit the most from the services.  It is expected that 22% of Americans 
will be aged 65 or older by 2050, and the number of people who are 85 years and older is 
expected to nearly double by 2035.9  Additionally, the geriatric population is at a higher risk of 
mood disorders such as depression – with as many as 49% of nursing home residents suffering 






care communities.12 The elderly also make up a large portion of patients from rural and remote 
locations and often have multiple chronic conditions, a situation which limits their ability to 
access specialized care.19 Even though depression is prevalent and the geriatric population is 
growing, access to geriatric psychiatrists is decreasing.5 These factors have created a need for 
telepsychiatry to bridge the gap between patients and providers.10 Telepsychiatry has the ability 
to connect psychiatrists to older adults in underserved or remote areas who would otherwise be 
unable to travel to the psychiatrist for treatment. 
Statement of Problem 
Telepsychiatry is a mainstream form of treatment used to address mood disorders in adult 
populations. Hearing loss affects 30% of adults aged 65 to 74, and 47% of adults over the age of 
74.13 Several studies have evaluated the effectiveness of telepsychiatry in the elderly population, 
but none has measured presbycusis and its impact on treatment outcomes in elderly patients with 
mood disorders such as depression. 
Objective 
  The purpose of our study is to assess whether telepsychiatry is superior to traditional 
face-to-face therapy among depressed geriatric patients suffering from presbycusis.  
 
Hypothesis 
 We hypothesize that Beck Depression Inventory II scores in depressed geriatric 
participants suffering from presbycusis will decrease from baseline to post-treatment clinically 










Telemedicine: Electronic transfer of medical and health information between distant sites and 
participants.1 
 
Telepsychiatry: The delivery of healthcare and the exchange of healthcare information for the 
purposes of providing psychiatric services across distances.6 
 
Presbycusis:  A progressive, bilateral and symmetrical sensorineural hearing loss due to age 
related degeneration of inner ear structures.21 
 
Depression: Depressed mood and/or loss of interest or pleasure in life activities for at least two 
weeks and at least five of the following symptoms that cause clinically significant impairment in 
social, work, or other important areas of functioning almost every day: Depressed mood most of 
the day, diminished interest or pleasure in all or most activities, significant unintentional weight 
loss or gain, insomnia or sleeping too much, agitation or psychomotor retardation noticed by 
others, fatigue or loss of energy, feelings of worthlessness or excessive guilt, diminished ability 
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Chapter 2 – Review of Literature  
Introduction 
To assess the current status of telemedicine in the geriatric population, we 
performed a review of the literature in the English language from January 2003 to 
December 2018 using Scopus and PubMed. The following search terms were used: 
(((telemedicine OR tele mental health OR telehealth OR tele-psychology OR tele 
psychology)) AND (older adults OR geriatrics OR veterans)) AND (depression) OR 
hearing loss) OR (presbycusis)))). We also performed a manual search of references from 
review articles.  

















































identified through other 
sources (n = 7) 
Records after duplicates removed 
(n = 252) 
Records screened (n = 252) 
Records excluded 
(n = 204) 
Full-text articles assessed 
for eligibility (n = 48) 
Full-text articles 
excluded, with 
reasons (n = 35) 






Inclusion criteria were as follows: the article had to test the outcomes of a video-
based form of telepsychiatry. The interventions had to include an accepted form of 
depression treatment (e.g. psychotherapy, medication management, etc.) in adult 
populations over the age of 18. Exclusion criteria included review articles, studies using 
telephone-based or automated interventions, deaf populations, and studies that did not 
assess patient outcomes as the main outcome variable. 
Once duplicates were removed a total of 252 articles remained and were screened 
for relevance using titles and abstracts. After screening articles based on titles and 
abstracts, 48 remained and were screened for the inclusion and exclusion criteria stated 
above. Thirteen articles remained for review. Of these, two papers described pilot studies 
prior to their subsequent randomized controlled trials (RCT); we focused only on the 
paper describing the final RCT. Two articles were excluded based on their inclusion of 
deaf individuals for telepsychiatry treatment interventions1,2 and no there were no articles 
that explicitly examined patients with hearing loss. Therefore, we focused on the 
available studies investigating the utilization of telepsychiatry for the treatment of 
depression in adults. 
The next section will briefly summarize the study designs and methods used 
followed by a more detailed analysis broken down by study design topic. 
Study Design 
Within the telepsychiatry literature, individual psychotherapy was examined in 13 
studies, including 6 randomized controlled trials,3-8 one randomized, open-label trial,9 






3 were superiority designs,6,7,15 2 were non-inferiority designs8,9 and 2 were equivalence 
designs.3-5 
Randomized Controlled Trials 
Superiority Randomized Controlled Trials 
Ruskin et al.6 were the first authors to perform a large scale RCT in 2004 
comparing telepsychiatry to in-person treatment of psychiatric illnesses in which they 
found no difference between treatment conditions. They recruited 119 participants from 
the Maryland Veterans Association. The treatment consisted of eight, 20-minute sessions 
with a psychiatrist over a 6-month period. Sessions addressed antidepressant medication 
management, psychoeducation and brief supportive counseling.  
In 2006, De Las Cuevas et al.,7 performed a RCT of 130 participants recruited 
from the Community Mental Health Centre of San Sebastian de la Gomera, in the Canary 
Islands and found no difference in outcome measures between face-to-face and 
telepsychiatry groups. The intervention was similar to that of Ruskin’s,6 consisting of 
eight, 30-minute sessions over 24 weeks and also required patients in both the face-to-
face and telepsychiatry groups to report to the same location for their care. But the 
authors7 differ by using a single provider for both the intervention and treatment as usual 
groups. This method allowed for more control of the patient-provider relationship, an 
important determinant for health outcomes, and also increased the internal validity of the 
study. However, using the same provider also introduces bias as the provider may favor 
one method over the other and unconsciously alter his/her interactions with patients.  
In 2013, Lichstein et al.10 underwent a pilot study which eventually led to the 21-






treatment of comorbid depression and insomnia by therapists through telepsychiatry 
resulted in better clinical outcomes than usual care with a primary care practitioner 
(PCP). There was no difference between experimental and control groups on a depression 
and sleep outcome measures. 
None of these three superiority RCTs found statistically significant differences 
between the face-to-face and telepsychiatry groups. Even though these studies are 
powered to detect statistically significant differences between treatment groups based on 
comparative methods rather than equivalence methods, often their authors incorrectly 
conclude that non-significant differences between groups implies equivalence. In order to 
address this issue, two subsequent authors present equivalency RCTs. 
Equivalence Randomized Controlled Trials 
O’Reilly et al.5 specifically designed and powered an equivalence study to 
determine whether telepsychiatry consultations for depression, which included optional 
monthly follow-up sessions for up to 4 months, were not inferior to face-to-face delivered 
sessions. 286 participants completed the study; equivalence was demonstrated between 
the telepsychiatry and face-to-face groups. 
Similarly, Choi et al.4 presents two studies, a preliminary efficacy trial and a 
subsequent equivalence RCT with 116 participants. Both studies report on the same 
experiment at different time points. The study design is a three-arm randomized control 
trial where the control group received 30 minute “support calls” from social workers, 
while the two treatment groups received six 60-minute face-to-face or telepsychiatry 
sessions focusing on problem solving therapy. This method differs from the previous 






group. The authors found that at follow-up, the telepsychiatry group had improved more 
than face-to-face and control groups on depression and disability measures. Although the 
difference was not statistically significant, the authors were unable to reject the null 
hypothesis of equivalence between telepsychiatry and face-to-face groups. 
The previous two studies used equivalence methods to determine whether the 
telepsychiatry intervention is neither worse nor better than face-to-face treatment or 
control condition. Equivalence trials are often confused with non-inferiority trials, whose 
main goal is to determine whether a new intervention is inferior to another or established 
intervention. Inferiority trials use a defined non-inferiority margin, based on clinical 
judgement and statistical considerations, which defines the limit of acceptable inferiority. 
Often non-inferiority designs are implemented for novel approaches to current successful 
therapies but may be beneficial or superior in other ways. For example, telepsychiatry has 
been shown to be as effective as face-to-face therapy, but it may also provide additional 
benefits such as decreased travel time, costs and increased accessibility. The following 
two studies implement a non-inferiority design. 
Non-inferiority Randomized Controlled Trials 
Egede et al.9 performed a non-inferior RCT in 2015 to assess telepsychiatry 
amongst older veterans suffering from depression compared to face-to-face treatment. 
They randomized 241 participants to either telepsychiatry or face-to-face therapy; 204 
participants completed the study. Using a non-inferiority margin of 15%, they found the 
telepsychiatry treatment to be non-inferior to face-to-face treatment. 
 The following year, Luxton et al.8 published a non-inferior RCT in which they 






face therapy (82 completed the study). Authors found slightly better results for in-person 
visits, but the difference was not statistically significant and based on the non-inferiority 
analysis, the null hypothesis could not be rejected. Thus, the study concluded that in-
home telepsychiatry was no worse than face-to-face psychotherapy. 
Observational Studies 
While RCTs are the “gold standard” of trials, they are often expensive, timely and 
difficult to achieve. Researchers can also draw valid conclusions from observational 
studies especially when an such a study is well designed and may even better reflect the 
“real world” than some RCTs. The following authors performed observational studies. 
Kennedy et al.12 recruited 124 participants who were referred for mental 
healthcare through telepsychiatry and compared them to those being seen face-to-face in 
rural Queensland. Participants were not randomized in this observational study and the 
effect of treatment was evaluated using the Mental Health Inventory (MHI)17—a 38-item 
self-reported measure of mental health issues—completed by participants, and Health of 
the Nation Outcome Scales (HoNOS)17—a 12-scale, clinician-rated measurement of 
health and social functioning, completed by practitioners. They found an improvement in 
both groups from baseline to post-treatment, but the groups did not differ statistically 
significantly.  
Griffiths et al.13 performed an observational study among 18 participants with 
depression and/or anxiety in Queensland that tested the effects of 6 to 8 weekly 
telepsychiatry CBT sessions had on clinical outcomes. They found statistically significant 
improvements from baseline to post-treatment among 48 participants. No control or 






Urness et al.14 measured patients’ satisfaction and patient outcomes in an 
observational study of patients receiving either face-to-face mental health or 
telepsychiatry care (not randomized). The telepsychiatry group showed a statistically 
significant improvement in pre- and post-intervention scores, while the face-to-face 
group did not. These difference between groups was not analyzed. 
The results obtained from these observational studies have limitations. For 
example, even though Urness et al.12 found improvements in the telehealth group and not 
in the face-to-face group, there may be some confounding factors between the groups that 
were not neutralized because of the study design. Furthermore, Kennedy et al.12 found 
improvements from baseline but it is not known whether these improvements were due to 
the intervention or may have occurred by chance given the lack of a control group. 
Case Studies 
Lastly, Lazzari et al.11 performed a small pilot study examining the effectiveness 
of Behavioral Activation Treatment for Depression (BATD) in older adults. In this study 
two out of the three patients improved sufficiently and no longer met the criteria for 
depression by post-treatment. All patients reported satisfaction with treatment by 
videoconferencing. Since the pilot study included only 3 participants, it is limiting in its 
ability to extrapolate findings to the general population. 
Patient Selection 
In general, recruitment of participants for the eleven studies occurred through the 
use of new or existing referrals for outpatient treatment of depression or self-referrals 
through print and radio advertisements,5,6,8,12,14 electronic medical records,7,9,15 case 






Several studies recruited participants from the Veterans Affairs Medical 
Center.6,8,9 One study recruited participants by mailing postcards to a mailing list, 
requesting that patients contact study coordinators if they felt that they were sad or 
depressed and were interested in participating in a clinical trial.9  
While the structure of the VA system provides easier avenues for patient 
recruitment, study trial participants are often homogeneous, leading to sample bias. For 
example, the majority of the VA participants in the Ruskin et al.6 trial were male (88%) 
and Caucasian (61%). Similarly, Egede et al.9 and Luxton et al.8 had comparable 
participant characteristics: 98% and 82% of their sample was male, and Caucasian (60% 
and 70%, respectively). Thus, women and minorities were vastly underrepresented in 
these samples and there were likely other characteristics within these groups that may 
present confounding factors.  
Another popular method of recruitment was through referrals from other health 
agencies or systems5,7,11-14,16 resulting in a participant pool already being seen in an 
existing healthcare system. This method of recruitment does not allow researchers to 
include patients who have not sought treatment for their mental health due to inability to 
access care or fear of stigmatization.  
In contrast, Choi et al.4 recruited patients through referrals from “Meals on 
Wheels” and other agencies serving low income seniors in Texas. Only older adults who 
were both low income and homebound were referred. This unique method targeted 
populations most in need of telehealth services – low income, homebound elderly adults 






Although we believe that older adults will benefit most from telehealth services, 
many of the studies included in this review excluded them. Specifically, a few studies 
consisted of adult populations with ages ranging from eighteen to sixty-five,5,8 eighteen 
to sixty14 or eighteen to fifty.6 Only two authors did not cap the upper age limit,7,12 and 
only three studies focused on the older population by including ages over 50, 58 and 65. 
4,11,15 One study did not supply information about the age of participants.13 In Luxton’s et 
al.8 study, a large portion of participants were employed and were required to leave work 
in the middle of the day to go home for their therapy session, which presents an obstacle 
for an employed adult.  In short, it is clear that further studies with more diverse 
populations and a focus on older adults is warranted.  
Table 1. Summary of Studies 
Author Study Design Sample 
Size 
Objective Method Findings 
Kennedy et 
al. (2003)12 










with case managers 
Improvements in 
both MHI and 
HoNOS scores from 
baseline to post-
treatment (p<0.01) 
but no difference 
between groups in 



















management of over 
the course of 6 
months  


















8 30-minute sessions 
of CBT and 
medication 
management over 24 
weeks delivered  
Improvement in 
both CGI and SLC-
90R scores from 
baseline to post-



















6-8 weekly CBT 
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sessions. No specific 






treatment in MCS 
measure (p=0.001) 
but not PCS 
(p=0.28). Face-to-
face group did not 
show improvement 














provided to PCP with 
optional month 
follow-up 
Both groups showed 
improvements in 
BSI score at follow-















Five 1-hour BATD 
sessions at 
psychiatric clinic 
Two out of three 
patients no longer 
met criteria for 
depression by post-
treatment 













Six 60-minute PST 
session via video 
conferencing or in-
person and control 
group received 30-
minute support calls 
from social workers  
Both in-person and 
tele-PST were more 
effective than 
control support calls 
based on HDS 
scores 
 (p=.001, p=.001, 
respectively) 












BATD sessions over 
8 weeks 









differences in GDS 







121 To compare 
telepsychiatry to 
face-to-face 
50 to 60-minute 
BATD sessions for  













reductions in BDI-II 






21 To compare 







10 sessions of 
integrated CBT-D 
and CBT-I performed 
by graduate students  
Non-significant 
decrease in HDS 
scores from baseline 
to post-treatment 
(p=0.14) 
Abbreviations: CBT: Cognitive Behavioral Therapy, MHI: Mental Health Inventory, HoNOS: Health of the Nation 
Outcome Scale, CGI: Clinical Global Impression, SLC-90R: Symptoms Checklist-90-Revised, MCS: Mental 
Component Score, PCS: Physical Component Score, BSI: Brief Symptom Inventory, BATD: Behavioral Activation 
Therapy for Depression, PST: Problem Solving Therapy, GDS: Geriatric Depression Score, BDI: Beck Depression 
Inventory, BDI-II: Beck Depression Inventory-II, BHS: Beck Hopelessness Scale, ITT: Intention to Treat, PCP: 
Primary Care Provider, CBT-D: Cognitive Behavioral Treatment for Depression, CBT-I: Cognitive Behavioral 




Five of the eleven articles had inclusion criteria consisting of major depression 
disorder (or other similar diagnosis such as dysthymic disorder or generalized anxiety 
disorder) as diagnosed by  DSM-IV criteria.6,8,9,11,13 Two studies based their inclusion 
criteria on the Hamilton Depression Scores (HDS):18 Ruskin et al.6 included participants 
who scored a 16 or higher on the HDS while Choi et al.4 included those who scored a 15 
or higher on the HDS. O’Reilly et al.5 used a score above 63 on the Brief Symptom 
Inventory (BSI)19 to determine participant eligibility. 
 Some studies did not narrow their inclusion criteria to any mental illness but 
rather included all patients who were referred by any source and identified by a 
practitioner as having a mental disorder, requiring mental health services.12,14,16 Such 
broad inclusion criteria with no specific diagnosis increases the generalizability of the 
study, but decreases the internal validity making it difficult to identify the effect 






In addition, one study did not implement a systematic way to evaluate participants 
for their inclusion diagnosis – Scogin et al.16 limited participants to those who had both 
depression and insomnia, but the participants were not required to have an official 
diagnosis of depression or insomnia. Instead they were required to have symptoms that 
were severe enough to require ongoing treatment from their primary care practitioner. 
Because participants were not diagnosed with depression or insomnia through the study 
protocol, it is arguable that this inclusion criterion is not robust and possibly led to bias in 
patient selection. 
Exclusion Criteria 
Authors excluded participants who met criteria for bipolar disorder,3,6 substance 
abuse or dependence,4,6,8,9,16 psychosis, 4,6,8,9,11,16 suicidal ideation or self-
harm,4,9,11,13,14,16,20 or if they were currently receiving psychotherapy8,11,16,21 or 
pharmacotherapy for depression.6   
Two authors excluded participants who demonstrated visual or hearing 
impairment (impairments were not operationalized or measured directly).4,11 
Furthermore, most authors did not take into account common disabilities in the elderly 
(such hearing loss, vision loss or decreased fine-motor skills) that impact their capability 
to use telehealth services. By failing to take into account confounding factors such as 
disabilities commonly found in certain patient populations, it is difficult for authors to 
draw accurate conclusions in their data. 
Table 2. Recruitment and Inclusion and Exclusion Criteria 
Author Age Population/Recruitment Inclusion Diagnosis Exclusion Diagnosis 
Kennedy et al. 
(2003)12 
>18 Consecutive sampling 
of patients being seen 
by practitioners for 
Any psychiatric 
disorder requiring 







mental healthcare in 
rural Queensland 
Ruskin et al. 
(2004)6 









substance abuse or 
dependence in past year, 
current pharmacological 
treatment for depression 
for > 1 month before 
initial visit 
De Las 




referred from PCP 
Substance abuse, 
psychosis, mood d/o, 
somatoform d/o, adult 
personality and 
behavior d/o (ICD-10) 
None 
Griffiths et al. 
(2006)13 
N/A Recruited through case 
managers 
MDD or mixed anxiety 
and depressive d/o, 
GAD, panic d/o with 
agoraphobia (ICD-10) 
Severe comorbid 
conditions, high risk of 
self-harm, poor English 
skills 
Urness et al. 
(2006)14 
18-60 Recruited from existing 
patients from 11 sites 
offering tele- or in-
person psychiatric 
treatment in Alberta, 
CA 
No specific diagnosis 
but no psychotherapy 




unable to consent, 
physically aggressive, 
agitated or suicidal 
O’Reilly et al. 
(2007)5 
18-65 Referrals from PCP in 
Ontario, CA 
BSI >62 If PCP believed them 
unable to consent, or if 
patients were referred for 
medico-legal issues 
Lazzari et al. 
(2011)11 
>64 Purposive sampling of 
patients from 
psychiatry clinic 
MDD or dysthymia 
(DSM-IV) 
Psychosis, SI, cognitive 
impairment, currently 
receiving psychological 
treatment, audio or 
visual impairments  
Choi et al. 
(2014)4 
>50 Homebound, served by 
senior agencies 
HDS>14 Psychosis, dementia, SI, 
bipolar, substance 
addiction, audio or visual 
impairments  
Egede et al. 
(2015)9 
>58 Veterans from VA 
hospital and four 
associated outpatient 
clinics 
MDD (DSM-IV) Psychosis, dementia, SI, 
current substance use or 
dependence 
Luxton et al. 
(2016)8 
18-65 Active duty members, 
reserve, national guard 
MDD (DSM-IV) Psychosis, SI, current 





Scogin et al. 
(2018)16 
>50 Patients were recruited 
from primary care 
clinics in mid-western 
Alabama 
Agreement of PCP of 




enough to warrant 
treatment 
Psychosis, SI, current 
substance use or 
dependence, cognitive 








Abbreviations: MDD: Major Depressive Disorder, DSM-IV: Diagnostic and Statistical Manual of mental disorders, 4th 
edition, HDS: Hamilton Depression Scale, ICD-10: International Classification of Disease, GAD: Generalized Anxiety 
Disorder, BSI: Brief Symptom Inventory, PCP: Primary Care Provider, SI: Suicidal Ideation 
 
Outcome Measures 
Depression was the primary outcome measure in all the studies included in the 
review. There are numerous validated outcome measurement tools for depression in the 
literature which include short assessments made by the provider, extensive self-reported 
surveys/questionnaires and clinician-delivered interviews, to name a few.  
Within our literature review, authors used the Hamilton Depression Scale 
(HDS),3,4,6,10,15 Geriatric Depression Score (GDS),9,11,22 Clinical Global Impression (CGI) 
ratings, Short Form Health Survey (SF-12),9,14,22 Brief Symptom Inventory (BSI),5 Beck 
Depression Inventory-II (BDI-II),6,8,9,22 Beck Hopelessness Scale (BHS)8, Symptom 
Checklist-90 Revised (SCL-90R)7, Structured Clinical Interview for Depression 
(SCID),9,22 Patient Health Questionnaire (PHQ-9),15 Mental Health Inventory (MHI)12,23 
and Health of the Nation Outcome Scale (HoNOS).12,13 
The most commonly used outcome measure of depression is the Hamilton 
Depression Score (HDS).4,6,16 Ruskin et al.6 used this 24-item scale in addition to 
measures of treatment adherence, patient satisfaction, psychiatrist satisfaction and 
resource consumption. Choi et al.4 used a modification of the Hamilton scale which 
included three additional items measuring hopelessness, helplessness and worthlessness.  
The efficacy of treatment in De Las Cuevas et al.’s7 study was measured with the 
Symptom Checklist-90 Revised (SCL-90R)24 global distress indexes and the Clinical 
Global Impression (CGI)25 ratings. The CGI is administered in approximately 2-minutes 
by the study psychiatrist and uses a 7-point Likert scale to assess severity of illness and 






relies heavily on the subjective evaluation of the clinician to assess for improvement in 
symptoms. Because the scale does not use more concrete markers for improvement and is 
performed by the patients’ psychiatrist, it is highly susceptible to bias because it cannot 
be assessed blindly. The SCL-90R is a self-reported, 5-point Likert scale measure, 
encompassing a broad range of psychological problems. While gathering data on such a 
broad range of issues is advantageous for assessing the psychological health of a patient, 
it may not be specific enough for evaluating depression-specific symptoms, which is the 
primary outcome of interest.  
Table 3. Outcome Measures 
Author Primary Outcome 
Kennedy et al. 
(2003)12 
MHI17: 38-item self-reported survey measuring distress and well-being 
 
HoNOS17: 12-item survey completed by clinicians, measuring behavior, symptoms 
and social functioning 
Ruskin et al. 
(2004)6 
HDS18: 17-item questionnaire administered by clinician on a Likert scale to assess 
severity of depression. 
De Las Cuevas 
et al. (2006)7 
SCL-90R22: Self-reported measure of psychological improvement based on 5-point 
Likert scale 
 
CGI25: Assesses treatment response in all categories of psychiatric patients; 
administered in 2-minutes by clinicians 
Griffiths et al. 
(2006)13 
MHI:17 38-item self-reported survey measuring distress and well-being 
 
HoNOS:17 12-item survey completed by clinicians, measuring behavior, symptoms 
and social functioning 
Urness et al. 
(2006)14 
SF-12:27 12-item self-reported survey of health 
O’Reilly et al. 
(2007)5 
BSI5: 53-item self-report of psychological symptoms and measures distress from 
these symptoms. 
Lazzari et al. 
(2011)11 
GDS26: 30-item self-report assessment used to identify depression in the elderly 
 
PANAS:27 A self-report questionnaire that consists of two 10-item scales to measure 
both positive and negative affect based on 5-point Likert scale 
 
Q-LES-Q:28 A self-report measure designed to enable investigators to easily obtain 
sensitive measures of the degree of enjoyment and satisfaction experienced by 







Choi et al. 
(2014)4 
Modified HDS: 17-item questionnaire administered by clinician on a Likert scale to 
assess severity of depression. Modification included three additional items measuring 
hopelessness, helplessness and worthlessness 
 
SF-12:29 12-item self-reported survey of health 
Egede et al. 
(2015)9 
SCID:30 Diagnostic exam used to determine psychological disorders 
 
BDI-II:31 21-question multiple-choice self-reported inventory of depression 
 
GDS:26 30-item self-report assessment used to identify depression in the elderly 
Luxton et al. 
(2016)8 
BHS:32 20-item self-report inventory used to assess hopelessness 
 
BDI-II:33 21-question multiple-choice self-reported inventory of depression 
Scogin et al. 
(2018)16 
HDS:18 17-item questionnaire administered by clinician on a Likert scale to assess 
severity of depression 
 
ISI:34 7-item self-reported questionnaire based on 7-point Likert scale used to assess 
the nature, severity, and impact of insomnia in adults 
 
Abbreviations: MHI: Mental Health Inventory, HoNOS: Health of the Nation Outcomes Scale, HDS: Hamilton 
Depression Scale, BSI: Brief Symptom Inventory, SLC-90R: Symptoms Checklist-90 Revised, CGI: Clinical Global 
Impression , SF-12: Short Form-12, BSI: Brief Symptoms Inventory, GDS: Geriatric Depression Scale, PANAS: 
Positive Negative Affect Schedule, Q-LES-Q: Quality of Life Enjoyment and Satisfaction Questionnaire , SCID: 
Structured Clinical Interview for DSM-IV, BDI-II: Beck Depression Inventory-II, ISI: Insomnia Severity Index 
 
Sample Size 
Studies vary in their sample sizes from 3 participants11 to 286 participants5 with 
an average of 100 participants (excluding case studies). Of the RCTs, drop-out rates 
varied from 7% to 48%, with an average drop-out rate of 27%. In the only RCT limited to 
elderly patients, most of the drop outs were due to hospitalizations, patients moving to 
nursing facilities or death.4  
Randomization and Blinding  
Neither the three observational studies nor the case study in this review were 
randomized or blinded. However, all the RCTs were randomized and often were further 
stratified by baseline characteristics such as age,7 depression severity,7 race/ethnicity9,16 
and recruitment site.8,16 Blinding of the RCTs occurred at baseline interviews9,16 and 






condition because questions were included that were specific to subject method – such as 
the ease and accessibility of telemedicine technology – which did not apply to the face-
to-face treatment groups. Nevertheless, assessors were blinded to the study hypothesis.4  
Telemedicine Technology 
The devices and equipment used for the transmission of telepsychiatry services 
differed among the studies reviewed here. The most common method was through a 
computer6,7 that had videoconferencing software installed and often included a 
camera,6,8,13,16 headphones,4,16 or speakers.13 A majority of the studies provided the 
telehealth sessions at a location other than the participants home such as at the local 
hospital or mental healthcare facility.5-7,11-13,16 This design allows authors to control for 
variables such as lighting, audio and privacy while also supporting on-sight technicians to 
aide in issues with connectivity. However, it does not allow authors to assess some 
positive effects of remote treatment such as convenience, reduced cost, reduced travel. 
Luxton et al.8 performed one of the only studies with in-home treatment. 
However, there were several limitations: the participants were middle-aged, employed 
and were expected to leave work to return home to attend the session, which negates 
many of the advantages that telehealth may offer in terms of accessibility and less fear of 
stigmatization. Most problematically, participants also experienced substantial technical 
difficulties in this study - out of all sessions, 36.3% were unable to initiate a webcam 
connection and 35.7% required a phone call to resolve a technical issue.  
All but one study9 connected to the Integrated Services Digital Network (ISDN) 
line, providing a 384 kilobit per second transmission in most cases.5-7,14 In instances 






movement.12,13 Participants in the Egede et al.9 trial used a videophone which was 
connected via a standard telephone service that was simple and easy to use. 
Table 4. Telemedicine Technology 
Author Technology Transmission Location 
Kennedy et al. 
(2003)12 
Venue 2000 and Swiftsite 
systems, PictureTel 
ISDN at 128 
kbit/s 
Local mental healthcare 
facility 
Ruskin et al. 
(2004)6 
VTEL software with cameras 
mounted on the monitors  
 
ISDN at 384 
kbit/s 
Clinic 
De Las Cuevas 
et al. (2006)7 
Viewstation 512 polycom ISDN at 384 
kbit/s 
University hospital 
Griffiths et al. 
(2006)13 
PC-based desktop with 
speakerphones and camera 
ISDN at 128 
kbit/s 
Mental health service facility 
Urness et al. 
(2006)14 
videoconferencing equipment ISDN at 384 
kbit/s 
In home 
O’Reilly et al. 
(2007)5 
Polycom 512 View Station and 
a Sony Trinitron screen 
N/A Local mental healthcare 
facility 
Lazzari et al. 
(2011)11 
videoconferencing technology 
and headsets provided by the 
university 
N/A University psychology clinic 
Choi et al. 
(2014)4 
Provided with laptops and 
headsets and used Skype 
software 
N/A In home 
Egede et al. 
(2015)9 
Videoconferencing via 








Luxton et al. 
(2016)8 
Provided with Dell M6500 
laptop and video camera and 
used Jabber video software (a 
Cisco Systems product 
N/A In home 
Scogin et al. 
(2018)16 
Skype Technologies combined 
with web cameras, a headset 
and microphone 
N/A Primary care office 
Abbreviations: ISDN - Integrated Services Digital Network  
 
Intervention 
The interventions used in the studies include problem solving therapy,4 
Behavioral Activation Treatment for Depression,8,9,11 medication management, 
psychoeducation, supportive counseling referrals to short-term psychotherapy 






Cognitive Behavioral Therapy.10,13 The number of sessions varied from five sessions11  to 
ten session,16 lasting anywhere from 20 minutes7 to 60 minutes.4,8,9,11 Several studies had 
follow-up periods ranging from 8 weeks16 to 12 months.9  
One of the most commonly known and used forms of psychotherapy is Cognitive 
Behavioral Therapy (CBT) which has been shown to be an effective treatment for many 
psychological disorders including depression.35 The treatment involves the patient 
recognition of unhelpful or distorted ways of thinking resulting in the modification of 
these thoughts and behaviors.  
In some studies, a remote certified psychologist delivered CBT sessions to 
participants while case managers observed and then reinforced the intervention while 
face-to-face with participants, following the session.12,13 The type of CBT delivered was 
based on the participants diagnosis. Those with depression focused on problem-solving, 
sleep, increasing activity and good eating behaviors.13 De Las Cuevas et al.7 incorporated 
eight, 30-minute CBT and medication management sessions over a 24-week period.  
In contrast, participants in the Scogin et al.16 study received CBT from graduate 
students in clinical psychology who had 4 days of didactic and experiential instruction. 
The limited training of graduate students providing psychotherapy is in contrast to other 
studies who delivered treatment through trained and experienced therapists, often with 
several years of experience with psychotherapy. 
Only one study used problem solving therapy (PST),4 which focuses on 
improving coping skills for high stress situations through instruction in specific problem-
solving steps. PST was delivered over six, 60-minute weekly sessions. Trained social 






Psychiatric consultations were used in another study.5 The consultations were 
administered to participants and a report was provided to the participants’ primary care 
provider. Consultations included follow-up appointments with the psychiatrist for up to 4 
months at monthly intervals if deemed clinically appropriate. The consultations 
themselves consisted of medical management, psychoeducation, supportive counseling 
and referrals to other local services such as psychotherapy. Psychiatrists were required to 
travel by plane and stay overnight in hotels while consulting face-to-face. Because of 
these travel commitments, psychiatrists may have been less likely to follow-up with face-
to-face consultations given the vast difference in time commitment required, thus 
increasing bias in treatment between the two groups. Furthermore, treatments varied 
between patients resulting in perhaps a more generalizable study, but one that may lack 
internal validity.  
Along with CBT, Behavioral Activation Therapy for Depression (BATD) was 
among the most popular intervention used in our review and has similar efficacy as 
CBT.35 It was more likely to be implemented among Veterans – both Egede et al.9 and 
Luxton et al.8 recruited participants from the VA and used BATD. Egede et al.9 reported 
their study was “the first randomized control trial of manualized evidence-based 
psychotherapy for depression in older adults with telemedicine” and differs from past 
studies in that it focuses on a robust model of psychotherapy (as opposed to medication 
management). Subsequent studies have taken this approach, using forms of 
psychotherapy like CBT as discussed above. In Egede’s study, participants all received 
behavioral activation for depression for weekly 60-minute sessions over 8 weeks.9 






that were of value to the patient. Much like the Egede study,9 participants in Luxton’s8 
study were provided with 50 to 60-minute behavioral activation treatment for depression 
every week for 8 weeks.  
Data Analysis 
 Across all the papers reviewed, mixed effects models were the most common 
analytic technique. In order to test for the significance of the difference between 
treatment and control groups, most studies used mixed effects models with a repeated 
measure design and used the significance of the interaction between treatment condition 
and time as the key outcome.4,6,9,21,36 This statistical method is well suited to the 
answering the key research question as it allows for significance testing of the treatment 
condition as well as allows the researchers to account for the change in effect of 
treatment condition over time. Mixed effects models also allow researchers to control for 
confounding factors such as initial depression severity or demographics like gender and 
age. One limitation of this method is that compared to simpler statistical methods it 
usually requires larger samples sizes.  
 We also found that chi-squared tests were a popular method: to use this method 
researchers dichotomized the outcome measure (typically splitting patients into those 
who experienced clinical remission and those who did not). The chi-squared test allows 
researchers to test whether the proportion of patients experiencing remission differed 
between the treatment and control groups; this method was often used as a complement to 








Most studies revealed improvements in outcome measures of depression from 
baseline to follow-up, whether treated with telepsychiatry or face-to-face therapy,4-8,11-13 
however, differences between groups were not statistically significant.5-9,12 Several 
studies were able to conclude non-inferiority8,9 or equivalence4,5 of telepsychiatry to face-
to-face treatment but no superiority study was able to conclude superiority of 
telepsychiatry over face-to-face psychiatry.6-8  
One possibility for these non-significant findings among the superiority studies 
could be due to their utilization of remote locations for their treatment sessions, thus 
negating the positive effects of remote sessions. The patients most in need of remote 
telepsychiatry are often those who are homebound, chronically ill with comorbid diseases 
and have difficulty ambulating and traveling to appointments. It is likely that this study 
design did not allow for homebound individuals to take part in the study. Similarly, the 
patient selection of all but one study4 did not allow for patient selection from the 
population of homebound adults—rather, selection was limited to those who had 
previously sought out and received healthcare services.  
Other confounding factors found in our review included recruitment exclusively 
from the VA healthcare system, resulting in a largely male and Caucasian participant 
population.6,8,9 Furthermore, most studies did not focus on the elderly population, often 
including participants over the age of 18 – only one study included participants over the 
age of 65.11 Inclusion criteria was too broad in several cases12,14,16 or not 






The most common interventions were psychotherapy (BATD8,9,11 or CBT10,13) 
which were delivered by trained and experienced providers in all but one study, which 
used graduate students with minimal training and no experience.16 Outcome measures 
were varied, with HDS being the most commonly used.3,4,6,10,15 The technology was 
similar in most studies, utilizing computer-based teleconferencing equipment connected 
to the internet in all but one study which implemented an analogue phone.9  
 There are many studies in the literature focusing on patient satisfaction with 
telepsychiatry. Although not the purpose of this review, some of the studies included in 
the review did report satisfaction measurements as a secondary analysis. One study found 
that homebound adults had higher approval rates of telepsychiatry than the face-to-face 
treatment groups,4 another reported moderate satisfaction,5 and one study had no 
difference in satisfaction.6 All three participants in the Lazzari et al.11 study reported 
satisfaction with treatment by videoconferencing.  
Conclusion  
Based on a review of the literature, telepsychiatry is at least as effective as face-
to-face therapy. However, more research on depression outcome measures targeted 
specifically at older, homebound adults is needed. When studying older patient 
populations, methods should be employed that will be most accessible to this population, 
such as delivering treatments in the participant’s home as opposed to a clinic or off-site 
study location. In addition, recruiting a more diverse population in both age, race and 
gender is important to the external validity of the study.  
Most importantly, our literature review concluded that there have been no studies 






encountered in older age. Controlling for hearing loss, impaired mobility and lack of 
familiarity with technology is important since these variables all impact the effectiveness 
of telepsychiatry delivery. In general, clinical studies tend to attract young and healthy 
adults and often exclude those with disabilities. It is important to include participants 
with disabilities so that interventions may be optimized to the complex populations they 
are designed to treat. In particular, late-life psychiatric conditions tend to be more 
complex and often co-morbid with other serious impairments, and it would be short-
sighted to investigate the effectiveness telepsychiatry in elderly populations without 
accounting for hearing loss, a common ailment found in this population.  
Due to the limitations found in the literature, we propose a study aimed towards 
the depressed, elderly population, who often suffer from presbycusis. We will to take this 
disability into account when the designing study methodology by directly measuring 
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Chapter 3 – Study Methods 
Study Design 
We will conduct a single-blind, randomized controlled trial powered to assess superiority 
of telepsychiatry over traditional, face-to-face psychotherapy. The groups will be assessed for 
depression using the Beck Depression Inventory II (BDI-II)1 at baseline (week 0), mid-treatment 
(week 4) and post-treatment (week 8). The primary outcome is clinical improvements in 
depression and the secondary outcome is patient satisfaction, assessed using the Charleston 
Psychiatric Outpatient Satisfaction Survey (CPOSS)1 at post-treatment.  
Outcome Measures  
Primary Outcomes 
The primary outcome measure will be the numerical change in BDI-II scores from 
baseline to post-treatment for each participant. BDI-II is a 21-item, self-reported, multiple-choice 
inventory that is a widely used indicator for the severity of depression. Each answer is scaled on 
a range of 0 to 3. Sum scores range from 0 to 63 with higher scores indicating increased 
depression severity. A score of 0 to 10 is categorized as “normal,” 11 to 16 as “mild mood 
disturbance,” 17 to 20 as “borderline clinical depression,” 21 to 30 as “moderate depression,” 31 
to 40 as “severe depression” and over 40 is considered “extreme depression.”  The BDI-II has 
good internal consistency (a=0.91)2 and high validity and is sensitive to change.3 
Changes in BDI-II scores in the telepsychiatry group will be compared to the face-to-face 
group. We hypothesize that there will be a clinically significant difference in pre-treatment to 







The secondary outcome measure is treatment satisfaction measured at mid-treatment and 
post-treatment using the CPOSS. The CPOSS is a 16-item Likert-scale response format that 
measures a patient’s satisfaction with his or her treatment. Scores range from 13 to 65, with 
higher scores representing increased satisfaction with treatment. We hypothesize that participants 
in the telepsychiatry group will have higher scores than those in the face-to-face group at both 
mid-treatment and post-treatment. We will also assess how the level of presbycusis affects 
clinical outcomes and patient satisfaction by correlating the level of presbycusis (discussed under 
“Hearing Loss” in “Study Variables and Measures” section) to BDI-II scores and CPOSS scores. 
Study Population and Sampling 
Study participants are male and female veterans and non-veterans. Veterans will be 
recruited from the VA mental health and primary care clinics; non-veterans are referred from 
healthcare professionals, self-referred via posted fliers in the community, or through agencies 
serving seniors in their homes. Inclusion criteria are as follows: participants aged 60 or older 
who—based on the Structured Clinical Interview (SCL) for the DSM-IV Axis I Disorders4—meet 
the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV)5 criteria for the 
following mood disorders: major depression disorder (MDD), mood disorder due to a general 
medical condition, adjustment disorder with depressed mood, dysthymic disorder (DD) or 
depression disorder not otherwise specified (NOS). Participants must score a 11 or greater on the 
Beck Depression Inventory II, indicating a depression severity of mild and above.6 They also 
must have age-related hearing loss as assessed using pure tone audiometry7 as well as have 
access to high speed internet in their home. Participants will be excluded if they have a DSM-IV 






cognitive impairment (Montreal Cognitive Impairment Assessment8 score of less than 26), if 
their living situation does not permit a private area for sessions to take place or if their corrected 
hearing in both ears does not allow them to hear below 90 dB, measured with pure tone 
audiometry.  
Recruitment 
We will use three methods for recruitment for eligible subjects. The first method will be 
an IRB approved sampling method in which we will systematically identify patients with any of 
the following diagnosis: MDD, mood disorder due to a general medical condition, adjustment 
disorder with depressed mood, dysthymic disorder or depression disorder not otherwise specified 
using the Veterans Affairs Connecticut Health Care (VACT) clinic billing records over the 
previous 12-months. We will contact providers of eligible patients in order to request permission 
to contact their patients regarding study enrollment. We will mail invitation letters to eligible 
patients. The letter will specify our interest in recruiting individuals with hearing loss and 
depression. The recruitment letter will include the following: information about the study, 
eligibility requirements, an addressed, stamped postcard that potential participants can return to 
indicate interest or decline participation in the study, and a phone number that participants can 
contact to obtain more information about the study, to make an appointment for study assessment 
or to decline the invitation. The letter will also inform the subject that they will receive a follow-
up phone call in two weeks if they have not returned the post-card or have not called to accept or 
decline the invitation. Once patients agree to participate, they will be asked to provide written 
consent and will be scheduled for a screening assessment. 
The second method will be a convenient sampling through self and provider referrals. 






primary care health clinics in CT and at senior centers throughout New Haven and surrounding 
communities. The fliers will describe the study and its eligibility requirements, as well as provide 
an email and phone number for subjects to contact if interested. The fliers will also be provided 
to clinicians who may refer patients to the study at their discretion. Clinicians may also obtain 
verbal consent from patients for study personnel to contact them.  Furthermore, we will present 
the study, its aims and subject requirements at physician and clinic staff meetings at the VACT 
and community primary care sites to encourage referral of eligible subjects.  
The final method of recruitment will be through the senior agencies such as Meals on 
Wheels, Senior Dine Program and “My Ride” transit. We will use IRB approved methods to 
systematically identify potential participants who meet the age criteria through the agencies 
records and send invitations to participate in our study. Participants interested in participating 
can then contact researchers who will answer any additional questions and schedule participants 
for an initial screening session.  
Screening and Baseline Questionnaires  
Once participants have agreed to participate, they will complete a written informed 
consent and undergo a baseline screening for depression, cognitive impairment, other psychiatric 
comorbidities and hearing loss. The baseline interview at week 0 will include a demographic 
questionnaire, a Montreal Cognitive Assessment (MoCA) screen, a structured clinical interview 
for DSM-IV (SCID-IV), the Beck Depression Inventory II (BDI-II) assessment, and a pure tone 
audiometry test. We will also ensure that patients taking antidepressants will be stabilized for 4 
weeks prior to initiating study treatment and will ask that providers maintain dosage, if possible, 






Demographic Questionnaire  
Demographic information will include age, race/ethnicity, occupation/work status, level 
of education, family income, living situation, marital status, branch of military service (if 
applicable), number of diagnosed chronic illnesses, number of diagnosed psychiatric illnesses, 
previous mental health treatment and number of medications including class of medications (e.g. 
antidepressants, sedative hypnotics, antipsychotics, mood stabilizers, stimulants, anti-
anxiolytics). 
Montreal Cognitive Assessment (MoCA)8 
The MoCA is a widely used screening tool for detecting cognitive impairment by 
assessing short-term memory, visuospatial abilities, attention, language and orientation. The test 
is scored from 0 to 30, with a score of 26 or over considered normal. Scores below 26 indicate 
cognitive impairment. The MoCA has good convergent validity and was superior to its 
counterpart exam, the Mini Mental Status Exam, in this regard.9  
Structured Clinical Interview for DSM-IV (SCID)4 
The SCID is a semi-structured interview that is considered the “gold standard” in 
diagnosing psychiatric disorders. The interview is performed by clinicians and incorporates 
current and past major depressive episodes, manic and hypomanic episodes, delusions, 
hallucinations as well as substance use disorders. The interview has been shown to have 
excellent validity.10 
Beck Depression Inventory II6  
Participants must score an 11 or greater on the Beck Depression Inventory II, indicating a 
depression severity of mild and above.6 Participants will complete the BDI-II questionnaire at the 






online with the clinician until the questionnaire is screened by the clinician for suicidal ideations 
(SI). If a participant responds to the suicidal thoughts or wishes question (question #9) as either 
“I have thoughts of killing myself, but I would not carry them out,” “I would like to kill myself,” 
or “I would kill myself if I had the chance to,” then researchers will inform the primary 
investigator (PI) who will speak with the patient via the phone, assess the subject’s safety, and if 
indicated, activate the local emergency medical service (EMS) to bring the patient to the closest 
emergency room for further evaluation.  If the subject is physically present and endorses a 
positive response on item #9 of the BDI-II, the PI will meet with the subject, assess the subject’s 
safety and escort the patient to the onsite emergency room for further evaluation, if required.   
Pure Tone Audiometry (PTA) Test 
The PTA test is the “gold standard” hearing test used to identify the decibel threshold at 
which an individual is able to hear. Patients are asked to indicate when they hear the “beep” of 
the machine. The resulting shape of the audiogram gives an indication of the type of hearing loss. 
In our study, uncorrected and corrected hearing loss will be assessed as described in the “Study 
Variables and Measures” section below. Participants will be excluded if they are able to hear 
below 25 decibels without correction (considered “normal” hearing) or if they are unable to hear 
below 70 decibels with correction in both ears. PTA is a valid test among older adults even 
without the use of a sound-treated environment.11 
Methodology 
Randomization 
A senior biostatistician will randomly assign participants into either control or 






sealed envelopes. This information will remain confidential in order to provide the study with a 
single-blind design.  
Blinding 
Due to the nature of the study design, neither the participants nor the clinicians providing 
the intervention will be blinded to the intervention. However, the researchers collecting the 
outcome data and baseline assessments will not be aware of the treatment condition, making this 
a single blind study. 
Data Collection 
We will use a secure, password protected electronic database to document participants’ 
medical and psychiatric diagnosis’, hearing assessments and questionnaires. In addition to 
baseline questionnaires and assessments, participants will repeat the BDI-II assessment at mid-
treatment and post-treatment. The CPOSS survey will be completed at mid-treatment and post-
treatment. 





MoCA PTA BDI-II CPOSS 
Baseline  
(week 0) 
X X X X X  
Mid-Treatment 
(week 4) 
    X X 
Post-Treatment 
(week 8) 
    X X 
 
Participant Protection and Confidentiality 
This proposal will be submitted for review to the VA and Yale Institutional Review 
Board (IRB) before proceeding with the protocol described. In addition, we will submit an 
application and supporting documents to the Human Subjects Committee (HSC) at the Yale 






Health Insurance Portability and Accountability Act of 1996 (HIPAA) privacy training and 
provide documentation of completion. Furthermore, all participants will be required to provide 
informed consent in order to participate in the study. Participants will be provided with detailed 
information regarding study protocols and any anticipated risks and benefits. They will be 
informed that their participation is voluntary and may be terminated at any point if they choose 
and their withdrawal will not affect their eligibility for future studies. Participants will not be 
considered for the study if they are unwilling or unable to provide consent. Finally, in 
accordance with state and federal law, all protected patient information will be securely stored 
and accessed via a password-protected electronic database. No physical participant records will 
be stored. All study personnel and clinicians will sign a confidentiality agreement.  
Study Variables and Measures 
Hearing loss 
The Center for Disease Control (CDC) defines the degree of hearing loss as a specific 
range of decibels (dB) that one can hear with their better ear. The CDC provides the following 
widely accepted ranges of defined hearing loss:7  
Table 6. Degree of Hearing Loss 
Hearing Ability Range (decibels) 
Normal hearing 0-25 
Mild hearing loss 26-40 
Moderate hearing loss 41-55 
Moderately severe hearing loss 56-70 
Severe hearing loss 71-90 







We will exclude normal hearing adults and condense the classifications into two groups 
as defined as mild/moderate hearing loss ranging from 25 to 55 dB, and severe hearing loss 
ranging from 56 to 90 dB. Participants will be assessed for corrected hearing loss with the use of 
their own hearing aids or those provided to them through the study. They will be excluded if 
their corrected hearing loss does not allow them to hear below 90 decibels.  
Corrected Hearing Loss 
Participants in the experimental group will be provided with Sony - ZX Series Wired On-Ear 
Headphones.12 The headphones are designed to fit comfortably over existing hearing aids and 
will allow for further sound amplification of the clinician during telepsychiatry sessions, while 
also reducing unwanted ambient noise. The control group will not use headphones since they 
will be receiving treatment in-person, however they will be permitted to use their own hearing 
aids.   
Psychotherapy Treatment 
All participants will receive 8 weekly 60-minute depression treatment sessions. The 
experimental group will receive sessions via telepsychiatry in their homes and the control group 
will receive sessions face-to-face in the clinic. For the treatment of depression, we will use the 
Behavioral Activation Treatment for Depression (BATD)13 method for both groups. The primary 
outcome will be effectiveness of the BATD treatment measured by the Beck Depression 
Inventory. The secondary outcome will be patient satisfaction with the treatment, measured by 
the Charleston Psychiatric Outpatient Satisfaction Survey.1   
Treatment Integrity  
Twenty percent of the sessions will be audio recorded and rated independently by an 






The expert reviewer will use a 7-point Likert scale rating form to assess how well the clinician 
accomplished the various behavioral tasks throughout the session. In addition, clinicians will be 
asked to rate themselves after each session using the same Likert scale as the expert reviewer.  
Behavioral Activation Therapy for Depression (BATD)13 
BATD is an efficient and effective depression treatment method which encourages 
patients to identify activities and individuals that bring them joy, and to therefore maximize 
contact with these sources. The therapy focuses on self-reflection through daily monitoring 
worksheets, life areas assessment worksheets, life activities checklists and identification of 
supportive people. It has good internal consistency, reliability and validity.14  
BATD was developed as a shorter form of behavioral activation (BA) after seminal work 
done by Lewinsohn (1974)15 found that the behavioral aspects of cognitive behavioral therapy 
(CBT) performed as well as CBT as a whole.15 Additionally, BATD has been shown to be an 
efficient and effective treatment for depression in adults13 and has been used in many 
telepsychiatry studies to compare the effect of telepsychiatry BATD to in vivo BATD.16-19 The 
fundamental aim of BATD therapy is to monitor daily activities in order to identify those 
activities which bring the greatest joy and maximize time spent engaged in those pursuits.  
In a meta-analysis of BADT consisting of 16 studies and 780 subjects, authors found a 
large effect size of 0.87.20 When compared to cognitive behavioral therapy (CBT)21 and 
antidepressants (paroxetine), it was found to be superior to CBT and comparable to 
antidepressants.22 Studies have also shown that older adults prefer counseling over 
antidepressants for the treatment of depression.23 Another form of depression psychotherapy is 
Acceptance and Commitment Therapy (ACT)24 which is a based on the concept that a patient 






therapy does not focus on a functional assessment like BATD but places more value more on 
acceptance of feelings. Compared to ACT, BATD is more action-focused and thus may be better 
suited for the large portion of veterans in our sample size, the majority of which are men. It has 
been demonstrated that men who suffer from depression are less likely to communicate problems 
verbally and more likely to act out by working more, engaging in risky behaviors and/or turning 
to alcohol or drugs.25 These action-oriented behaviors suggest that veterans may respond better 
to action-oriented therapy compared to cognitive-oriented therapy. Lastly, compared to other 
forms of psychotherapy, BATD is relatively simple, time-efficient and does not require complex 
skills from the patient nor does it require intensive training of the therapist. For these reasons, we 
concluded that BATD would be the best treatment modality for our study.  
The revised manual of BATD consists of 5 treatment sessions with an additional 5 
sessions to review concepts and engage in post-treatment planning. Although there has been no 
formal systematic comparison of BATD treatment length and its efficacy, 10 sessions is a 
standard length, with even shorter protocols producing benefits.26,27 Our study will use 8 
sessions.  
Beck Depression Inventory II (BDI-II)6 
The BDI-II consists of 21 questions scored on a scale of 0 to 3 with higher scores 
indicating more severe depression. It is the most widely used self-reported depression inventory 
tools in use. It has a Pearson r of .71 correlation with the Hamilton Depression Rating Scale and 
a one-week test-retest rating of Pearson r of .93, making it a very effective tool among self-
reported measurement instruments.6 The internal consistency was rated high (a=0.89) among 






 Although the BDI-II measurement has good reliability and consistency, it is still 
vulnerable to patient exaggeration or minimization because it is a self-reported measure. 
However, we expect this confounding factor to be minimized since our study will be comparing 
scores from pre-treatment to post-treatment among the same individuals.   
Charleston Psychiatric Outpatient Satisfaction Survey (CPOSS)1 
The CPOSS is a 16-item Likert-scale response survey that measures a patient’s 
satisfaction with their treatment. Scores range from 13 to 65, with higher scores representing 
increased satisfaction with treatment. In a sample population, Egede et al. (2009), found that this 
measure had excellent reliability (Cronback’s alpha = 0.96) and good validity with relevant 
anchor items (“would you recommend this treatment to a friend or family member?”) among 
elderly veterans treated for depression through telepsychiatry.29 Although some of the items on 
the scale are only relevant to clinic-based practices, there is an “Not Applicable” option and 
scores will be calculated by blinded researchers in order to take these answers into account.  
Sample Size Calculation 
We would like to demonstrate superiority of telepsychiatry compared to face-to-face 
psychotherapy among geriatric participants with presbycusis. The primary outcome measure is 
the numerical difference in the BDI-II score from baseline to post-treatment. In order to calculate 
the sample size required for this continuous outcome superiority trial, we used the previously 
identified clinically significant effect size of 5 for the BDI-II30 with a standard deviation of ten.31 
To achieve 80% power on a one-sided test to detect this difference with a significance level of 
5%, it is estimated that 113 subjects per group would be required. After accounting for a 20% 
drop-out rate, 137 subjects per group or a total of 274 subjects will be recruited (see Appendix I 







Inferential statistics will be used to compare the baseline characteristics of each group to 
ensure adequate randomization. We will also report baseline characteristics as proportions for the 
dichotomous variables and as means and standard deviations for the continuous variables. Prior 
to analysis, we will implement a last observation carried forward (LOCF) method to compare 
patients who dropped out to those who persisted in the study to ensure that there are not 
significant differences between the groups.  
Our null hypothesis is that depression treatment delivered via telepsychiatry is superior to 
treatment delivered face-to-face among geriatrics patients suffering from presbycusis.  The 
primary outcome will be change in depression score, measured by the BDI-II, between baseline 
and post-treatment. Using a univariate method, we will compare the differences in baseline and 
post-treatment depression scores between treatment and control groups using a T-test. 
Additionally, following the design of similar studies in the literature, the primary outcome 
measure will be analyzed using a linear mixed effects model. This is often preferable to 
univariate analysis because it allows us to control for potential confounding factors and to better 
understand the trajectory of depression scores over multiple measurements (baseline, mid-
treatment and post-treatment).  
To model this, we will consider the baseline, mid-treatment and post-treatment measures 
as “repeated measures” and construct a mixed effects model to assess the effect of treatment 
group on depression score. In this model the dependent variable is depression score, and the key 
independent variables are (1) treatment group, (2) time (measured in weeks since patient intake) 
and (3) the interaction of treatment group and time. This will allow us to test both whether 






whether patients in the treatment group improved at the same or different rate compared with 
patients in the control group. This analytic method is well suited to this problem because we can 
use patient background characteristics as covariates (including age, initial severity of depression 
and severity of hearing loss) and because it allows us to investigate the trajectory of depression 
scores over time.   
Timeline and Resources  
Timeline 
Study personnel will be recruited four months before initiation of the start of subject 
recruitment and will undergo personnel-specific training as described below. We expect 
participant recruitment to commence in October of 2019 and continue until October of 2020. 
Participants will begin the 16-week study treatment on a rolling basis, with the last treatment 
scheduled to end by March 2020. Data entry will be completed on a rolling basis, and analysis is 
expected to be completed by June 2020. Completion of the study, which includes study 
personnel training, recruitment, therapeutic intervention and data analysis will take 24 months in 
total.  
Research Assistants 
Research assistants (RA) will be volunteer senior psychology majors or graduate 
psychology students recruited by the psychology department at Yale University through fliers 
and student interest group postings. We will recruit 5 to 6 RA’s and their responsibilities will 
include placement of fliers as directed by the study coordinator, as well as receiving calls from 
potential participants, providing them with information about the study, directing calls to the PI 






Senior Biostatistician  
This role will be filled by a volunteer biostatistician who will have a minimum of two 
years of experience as a biostatistician with experience working in a research setting. The 
biostatistician will provide randomized participant assignments to the study coordinator in a 
blinded fashion. He/she will also be available to the PI for statistical consultation during the 
analysis phase. 
Study Coordinator 
The study coordinator will be the Principle Investigator (PI) and will be responsible for 
ensuring all study personnel complete their required training and will be available to support 
their responsibilities. They will not be involved in data gathering or treatments and will remain 
blind to the conditions throughout the study. The PI will be a licensed independent practitioner, 
qualified to assess a participants’ physical health, psychological status and suicidality. 
Treatment Clinicians 
Four to five board certified clinical psychologists with at least three years of clinical 
experience will be recruited from clinicians working at the VA or in the community through 
fliers and emails. They will undergo a two-week training course on BATD as well as training on 
the remote software. Their main responsibility will be to provide BATD to study participants.  
Outcome Measures Clinicians 
Three to four board certified clinical psychologists with at least three years of clinical 
experience will be recruited from clinicians practicing at the VA or in the community to 
complete all initial SCID and MoCA evaluations. Initial screening and baseline measurement 
will be completed in the clinic for all participants, thus blinding clinicians to treatment 






completed by participants after their 4th and 8th sessions while clinicians remain on-line or in the 
clinic. Clinicians will review the BDI-II question number 9 (assessing for suicidality), before 
ending the session with the participant, and will take further action by informing the PI if the 
study participant screens positive for SI. All study personnel will be required to complete 
HIPAA training and to sign a confidentiality agreement.  
Videoconferencing Equipment  
Google’s Duo videoconferencing system will be used for telepsychiatry sessions. The system 
is optimized for low bandwidth networks and provides high-definition video calls. It also offers 
default end-to-end encryption for safety and privacy.32 Inclusion criteria includes access to a 
computer in the home as well as high speed-internet (defined as having an Integrated Services 
Digital Network (ISDN) or Digital Subscriber Line (DSL) connection). Therefore, set-up for 
Google’s Duo’s videoconferencing system will only require participants to navigate to the 
website, enter their phone number, and enter the system-provided verification code sent to the 
participant’s phone. 
Sound Amplifiers  
The experimental group will be provided with Sony - ZX Series Wired On-Ear 
Headphones12 which will amplify the telepsychiatry sessions. Participants will be able to wear 
their own hearing-aides simultaneously.  
Research Staff Workroom 
Several private rooms in VACT or Yale Medical School will be designated for clinical 
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Chapter 4 – Conclusion 
 
Telepsychiatry is an expanding field but many studies have focused on patient 
satisfaction rather than outcome measures. Furthermore, of those that investigate outcome 
measures, few include the geriatric population, even though this population is growing and may 
be particularly in need of remote treatment for chronic illnesses such as depression. Geriatric 
patients have more difficulty coordinating transportation to appointments, may be geographically 
isolated, and have age-related physical impairments which may make the delivery of healthcare 
more accessible when provided remotely. Our study focuses on outcomes among this 
disadvantaged population of older adults with age related hearing loss.  
Advantages and Disadvantages 
Our study specifically measures hearing loss as a confounding variable using pure tone 
audiometry, a method that has not been used before and will be vital in providing information on 
the impact hearing loss has on the success of telepsychiatry among geriatric patients. We have 
chosen to exclude patients who are clinically deaf as this population requires a different set of 
interventions such as American Sign Language (ASL) interpreters; fortunately, there is another 
set of literature addressing this population.1,2 Furthermore, to ensure patient diversity, we have 
recruited subjects from the VA hospital, connunity primary care clinics and senior agencies with 
the goal of expanding our study population to elderly who are homebound and may not be 
currently receiving medical care. We also plan to provide our telepsychiatry intervention in the 
participants home. While this design does not allow for a carefully controlled setting, it will 
allow us to appreciate the effectiveness of the intervention in vivo. 
There are several limitations in our study. First, although our sample size is large enough 






complete the study in a two-year timeframe and more time may be needed to recruit patients. 
Second, the sample size also may not be large enough to detect the association between levels of 
presbycusis and outcome measures. Third, a third arm ideally would be added to the design, 
representing a “true” control that would allow us to not only compare telepsychiatry to face-to-
face depression treatment but also to compare it to a placebo-like interaction such as support 
calls. However, adding a third arm dramatically increases the sample size required to detect 
significance between groups and would not be feasible within our limited timeline and resources. 
Since we do not want to confound any treatment of depression with the specific remote 
intervention we are implementing, we have chosen to compare our intervention to the standard 
treatment protocol as opposed to a placebo treatment. 
Fourth, our study is a single-blind study because it is not possible to blind the participants 
to the intervention of telepsychiatry or face-to-face psychiatry. While a double-blind study is 
ideal, our intervention presents limitations in this regard. Nevertheless, we have blinded 
assessors and researchers to treatment conditions at all other data collection points. A fifth 
limitation is the lack of follow-up. Ideally, a lengthy follow-up period would allow us to 
determine the long-term outcomes of telepsychiatry treatment.  
Public Health Significance 
Overall, this study represents a novel contribution to the field through its focus on the 
provision of telepsychiatry in hearing impaired older adults and its recruitment of a diverse 
patient population. The evidence that the elderly population is accepting of a videoconferencing 
as a form of therapy3 means that such a method is scalable to meet the needs of this population. 
As the field of telemedicine grows, the technology will be become cheaper and more accessible 






delivered to designated rural-area residents.4 Thus, the policies surrounding Medicare 
reimbursement for telemedicine services should be addressed and include disadvantaged 
populations such as the elderly and homebound individuals. The results of our study will impact 
future therapies directed towards older adults and contribute to the growing support of 









1. Lopez AM, Cruz M, Lazarus S, Webster P, Jones EG, Weinstein RS. Use of American 
Sign Language in telepsychiatry consultation. Telemedicine journal and e-health : the 
official journal of the American Telemedicine Association. 2004;10(3):389-391. 
2. Crowe TV. Is Telemental Health Services a Viable Alternative to Traditional 
Psychotherapy for Deaf Individuals? Community mental health journal. 2017;53(2):154-
162. 
3. Choi NG, Wilson NL, Sirrianni L, Marinucci ML, Hegel MT. Acceptance of home-based 
telehealth problem-solving therapy for depressed, low-income homebound older adults: 
qualitative interviews with the participants and aging-service case managers. 
Gerontologist. 2014;54(4):704-713. 
4. Medi- care carriers manual part 3 – Claims process: Section 15516: Medicare payment 
for telehealth services. In: (CMS) CfMaMS, ed. Washington, DC.2003. 
1. Lopez AM, Cruz M, Lazarus S, Webster P, Jones EG, Weinstein RS. Use of American 
Sign Language in telepsychiatry consultation. Telemedicine journal and e-health : the 
official journal of the American Telemedicine Association. 2004;10(3):389-391. 
2. Crowe TV. Is Telemental Health Services a Viable Alternative to Traditional 
Psychotherapy for Deaf Individuals? Community mental health journal. 2017;53(2):154-
162. 
3. Choi NG, Wilson NL, Sirrianni L, Marinucci ML, Hegel MT. Acceptance of home-based 
telehealth problem-solving therapy for depressed, low-income homebound older adults: 
qualitative interviews with the participants and aging-service case managers. 
Gerontologist. 2014;54(4):704-713. 
4. Medi- care carriers manual part 3 – Claims process: Section 15516: Medicare payment 
for telehealth services. In: (CMS) CfMaMS, ed. Washington, DC.2003. 
1. Lopez AM, Cruz M, Lazarus S, Webster P, Jones EG, Weinstein RS. Use of American 
Sign Language in telepsychiatry consultation. Telemedicine journal and e-health : the 
official journal of the American Telemedicine Association. 2004;10(3):389-391. 
2. Crowe TV. Is Telemental Health Services a Viable Alternative to Traditional 
Psychotherapy for Deaf Individuals? Community mental health journal. 2017;53(2):154-
162. 
3. Choi NG, Wilson NL, Sirrianni L, Marinucci ML, Hegel MT. Acceptance of home-based 
telehealth problem-solving therapy for depressed, low-income homebound older adults: 
qualitative interviews with the participants and aging-service case managers. 
Gerontologist. 2014;54(4):704-713. 
4. Medicare carriers manual part 3 – Claims process: Section 15516: Medicare payment for 









Form 1. Invitation to Potential Participants 
 
Hi, my name is Stephanie Mock and I am a graduate from the Yale University Physician 
Associate program. I am conducting a research study to examine the impact of therapy 
(Behavioral Activation Treatment for Depression (BATD)) on older individuals suffering from 
depression and hearing loss. Our records indicate that you are a potential candidate for our study.  
 
Participation in this study will involve completing baseline questionnaires, a complete hearing 
evaluation, and follow-up questionnaires at the end of the study. The majority of your time will 
be involve participating in either online (from your home) or in-person psychotherapy sessions 
with a licensed clinical psychologist. These will consist of 8 weekly 1-hour sessions and include 
weekly assignments, daily journals and thoughtful discussion with the clinician. Your 
involvement will require about 1 hour/week for 10 weeks.  You will not be expected to pay for 
the therapy sessions, nor will you be compensated for your participation. 
 
The ideal candidate for participation in this study is one who has access to high speed internet, 
has a private space in the home, has some trouble hearing in one or both ears, and suffers from 
depression. 
 
If you are interested in finding out more about this study, please call one of our researchers at 
###-###-####. 
 
If you know whether or not you would like to participate in this study, please indicate so on the 
attached form and send using the pre-addressed and stamped post-card. You may also call the 
number above to indicate your interest or disinterest. If we do not receive a response within 2 
weeks, we will call to confirm your response to the invitation. 
 
 























Our study is evaluating various outcomes in 
depressed geriatric participants with presbycusis 
(hearing loss) who are treated with Behavioral 
Activation Therapy for Depression via 
telepsychiatry. We are seeking research assistants for 
data entry and interviewing potential subjects. Ideal 
candidates will be senior psychology majors or 
graduate psychology students. Please email 









Our study is evaluating various outcomes in 
depressed geriatric participants with presbycusis 
(hearing loss) who are treated with Behavioral 
Activation Therapy for Depression (BATD) via 
telepsychiatry. We are seeking clinical psychologists 
to provide BATD in person or through 
telepsychiatry. Please email 








Form 2. Informed Consent 
 
Title: Effectiveness of Telepsychiatry Among Geriatrics with Age-Related Hearing Loss 
  
Researcher(s):  Stephanie Mock, Yale Physician Associate Program 
 Michelle Conroy, MD Yale School of Medicine  
  
Researcher Contact Info: ###-###-#### 
 stephanie.mock@yale.edu 
You are being asked to participate in a research study. The box below highlights key information 
about this research for you to consider when making a decision about whether or not to 
participate. Carefully consider this information and the more detailed information provided 
below the box. Please ask questions about any of the information you do not understand before 
you decide whether to participate. 
Key Information for You to Consider 
• Voluntary Consent. You are being asked to volunteer for a research study.  It is 
up to you whether you choose to participate or not.  There will be no penalty or 
loss of benefits to which you are otherwise entitled if you choose not to 
participate or discontinue participation. 
• Purpose. The purpose of this research is to assess effects that Behavioral 
Activation Treatment for Depression (BATD) has on older individuals suffering 
from depression and hearing loss. 
• Duration. It is expected that your participation will last 5 months. 
• Procedures and Activities. You will be asked to participate in 8 weekly online 
or in-person BATD sessions with a trained clinician, to complete all aspects of 
the treatment protocols, including but not limited to weekly assignments, daily 
journals and thoughtful discussion with the clinician. You will also be asked to 
complete questionnaires throughout the course of the study as well as complete 
one full audiometric assessment at the start of the study.  
• Risks. Some of the foreseeable risks or discomforts of your participation include 
discussion of topics that may cause emotional distress, suicidal ideations or 
thought of harming others or yourself. 
• Benefits. Some of the benefits that may be expected include receiving treatment 
for depression and learning how to cope with depression in the long-term. 
• Alternatives. Participation is voluntary and the only alternative is to not 
participate. 
 
The researcher(s) Stephanie Mock and Michelle Conroy from Yale University are asking for 
your consent to this research. 
 
The purpose of the research is to evaluate the effectiveness of depression therapy through 






asked to participate because you have met criteria for age, potential hearing loss and potential 
depression diagnosis.  About 150 people will take part in this research.   
If you agree to be in this research, your participation will include: assessment of hearing loss, 
baseline questionnaires to evaluate your physical and mental health, participate in depression 
treatment with a trained clinician through videoconferencing in your home or at the study 
headquarters.  
 
We will tell you about any new information that may affect your willingness to continue 
participation in this research. 
What happens to the information collected for this research? 
Information collected for this research will be used to compare to other participants’ information 
in order to discern how differences in treatment may affect depression symptoms and how 
differences in participant characteristics effect how they respond to treatment types. 
How will my privacy and data confidentiality be protected? 
We will take measures to protect your privacy including storing data in password protected 
database. Despite taking steps to protect your privacy, we can never fully guarantee your privacy 
will be protected.   
 
Individuals and organization that conduct or monitor this research may be permitted access to 
and inspect the research records.  This may include access to your private information and 
electronic medical records. These individuals and organizations include: the primary research 
investigator, clinicians, staff biostatistician and research assistants. All study personnel will 
undergo Health Insurance Portability and Accountability Act of 1996 (HIPAA) privacy training 
and provide documentation of completion. 
What if I want to stop participating in this research? 
Taking part in this research study is your decision. Your participation in this study is voluntary. 
You do not have to take part in this study, but if you do, you can stop at any time.  You have the 
right to choose not to participate in any study activity or completely withdraw from continued 
participation at any point in this study without penalty or loss of benefits to which you are 
otherwise entitled. Your decision whether or not to participate will not affect your relationship 
with the researcher, Veterans Affairs, senior agencies or Yale University. 
Who can answer my questions about this research? 
If you have questions, concerns, or have experienced a research related injury, contact the 






If you would like to talk with someone other than the researchers to discuss problems or 
concerns, to discuss situations in the event that a member of the research team is not available, or 
to discuss your rights as a research participant, you may contact the Yale University Human 








STATEMENT OF CONSENT 
I have had the opportunity to read and consider the information in this form.  I have asked any 
questions necessary to make a decision about my participation. I understand that I can ask 
additional questions throughout my participation. 
I understand that by signing below, I volunteer to participate in this research. I understand that I 
am not waiving any legal rights. I have been provided with a copy of this consent form. I 
understand that if my ability to consent or assent for myself changes, either I or my legal 
representative may be asked to re-consent prior to my continued participation in this study. 
 
I consent to participate in this study.  
 
      
Name of Adult Participant Signature of Adult Participant      Date 
 
Researcher Signature (to be completed at time of informed consent) 
I have explained the research to the participant and answered all of his/her questions. I believe 
that he/she understands the information described in this consent form and freely consents to 
participate.  
 
      
























Form 4. Demographics and Psychiatric Questionnaire  
 
Patient’s Name: _______________________________________________________________ 
Date of Birth: ____/____/____ Patient’s Birthplace:__________________ Sex: __M __F  
Race: __ African-American __ Caucasian __ Hispanic __ Asian __  Other ______________  
Who referred you this study? _________________________________________________   
 
Have you ever received outpatient mental health treatment? __ No __ Yes  
If yes, please list in order:  
Clinician/ Doctor Date(s) of Evaluation 
or Treatment 
Type of Evaluation or 
Treatment 
Frequency of visits 
    
    
    
    
    
 
Have you ever received inpatient mental health treatment? __  No __ Yes  
If yes, please list in order:  
Hospital Name Dates of Treatment Reason for hospitalization 
   
   
   
 
If you have ever taken psychiatric medications, please list them below: ‰ Not applicable Rx  




      
      
      
      
      
      
      
 
 
Have you ever had any brain imaging or functional studies? (MRI, CAT scan, EEG, etc.)  
 __ No __ Yes  
 







Please describe your past or current use of any of the following substances: 
 __ Never tried any Substance  
 
Substance Age at 1st use Frequency of 
use 





ALCOHOL      
TOBACCO      
MARIJUANA      
COCAINE      
AMPHETAMINE      
ECSTACY      
LSD/ ACID      
OPIATES      




     
 
Have you ever received inpatient or outpatient substance abuse treatment? __  No __ Yes  
 
Medical History  
 
Who is your Internist or Family Doctor?  __ Do not have a doctor 
________________________________________________  
When was your last physical examination? 
______________________________________________  
 
Current Medications (include Over-the-counter meds, Vitamins, Herbs, or Supplements) 
 __ None OR Please List:  
Rx Name Dosage Frequency Prescribing M.D. 
    
    
    
    
    
    
    
 
Do you have any drug allergies? ………………………………__  No __ Yes (please list): 
______________________________________________________________________________
Do you have any current medical problems? ………………….__  No __ Yes (please list): 
______________________________________________________________________________
             








City of Residence: _____________________________  
Now Living with: __ Spouse __ Children __ Roommate __ Other:_____________________  






Work Status:  
___ Employed   ___Retired ___Unemployed  ___On disability  ___Other 
 
If “Other” please explain: ________________________________________________________ 
 
School History  
 











Form 5. BATD Schedule of Treatment 
 
1. Session 1 
a. Introduction  
b. Discussion of Depression 
c. Introduction to Treatment Rationale  
i. What about trauma and loss in your life? 
ii. Why is coming every week important?   
d. Introduce Daily Monitoring (Form 1) 
i. Importance and Enjoyment Ratings 
e. Introduce and Complete Contracts Part 1: Identifying Supportive People (Form 2: 
Top Part) 
f. Important Points about the Structure of This Treatment 
 
2. Session Two 
a. Review Daily Monitoring (Form 1) 
b. Review Contracts Part 1: Identifying Supportive People (Form 2: Top Part)  
c. Introduce and Complete Life Areas and Values (Form 3) 
3. Session Three  
a. Review Daily Monitoring (Form 1) 
b. Review and Edit Life Areas and Values (Form 3) 
c. Introduce and Complete Life Activities Checklist (Form 4) 
4. Session Four 
a. Review Daily Monitoring (Form 1) 
b. Review Life Activities Checklist (Form 4) 
c. Introduce and Complete Activity Selection and Ranking (Form 5) 
d. Introduce and Complete Activity Hierarchy (Form 6) 
5. Session Five 
a. Review Daily Monitoring (Form 1) 
b. Review and Edit Activity Selection and Ranking (Form 5) 
c. Review and Edit Activity Hierarchy (Form 6) 
d. Introduce and Complete Activity Planning (Form 1) 
6. Session Six 
a. Review Daily Monitoring (Form 1) 
b. Review and Complete Activity Planning (Form 1) 
c. Introduce and Complete Contracts Part 2: Getting Help from Supportive People 
(Form 2: Bottom Part)  
7. Session Seven 
a. Review Daily Monitoring with Activity Planning (Form 1) 
b. Review and Edit Contracts Part 2: Getting Help from Supportive People (Form 2: 
Bottom Part)  






d. Review Daily Monitoring with Activity Planning (Form 1) 
e. Review Concept and Edit Activities (Forms 4, 5, and 6) 
f. Complete Activity Planning (Form 1) 
g. Review Concept and Edit Contracts (Form 2: Top and Bottom Part) 
h. Complete Activity Planning (Form 1) 
8. Session Eight 
a. Review Daily Monitoring with Activity Planning (Form 1) 
b. Review Concept and Edit Life Areas and Values (Form 3) 
c. Complete Activity Planning (Form 1) 
d. Prepare for Termination: Continuation of Daily Monitoring with Activity 
Planning (Form 1) 
 
List of Forms 
Form 1. Daily Monitoring (with Activity Planning starting in Session 6) 
o Therapist Manual: One copy 
o Patient Manual: 84 copies (one for each day of treatment) 
Form 2. Contracts 
o Therapist Manual: One copy 
o Patient Manual: 10 copies 
Form 3. Life Areas Assessment 
o Therapist Manual: One copy 
o Patient Manual: One copy 
Form 4. Life Activities Checklist 
o Therapist Manual: One copy 
o Patient Manual: One copy 
Form 5. Activity Difficulty Assessment 
o Therapist Manual: One copy 
o Patient Manual: One copy 
Form 6. Activity Hierarchy 
o Therapist Manual: One copy 










Form 6. BDI - II 
 
Instructions: This questionnaire consists of 21 groups of statements. Please read each 
group of statements carefully. And then pick out the one statement in each group that 
best describes the way you have been feeling during the past two weeks, including 
today. Circle the number beside the statement you have picked. If several statements in 
the group seem to apply equally well, circle the highest number for that group. Be sure 
that you do not choose more than one statement for any group, including Item 16 
(Changes in Sleeping Pattern) or Item 18 (Changes in Appetite). 
 
1. Sadness 
0. I do not feel sad. 
1. I feel sad much of the time. 
2. I am sad all the time. 
3. I am so sad or unhappy that I can't stand it. 
2. Pessimism 
0. I am not discouraged about my future. 
1. I feel more discouraged about my future than I used to. 
2. I do not expect things to work out for me. 
3. I feel my future is hopeless and will only get worse. 
3. Past Failure 
0. I do not feel like a failure. 
1. I have failed more than I should have. 
2. As I look back, I see a lot of failures. 
3. I feel I am a total failure as a person. 
4. Loss of Pleasure 
0. I get as much pleasure as I ever did from the things I enjoy. 
1. I don't enjoy things as much as I used to. 
2. I get very little pleasure from the things I used to enjoy. 
3. I can't get any pleasure from the things I used to enjoy. 
5. Guilty Feelings 
0. I don't feel particularly guilty. 
1. I feel guilty over many things I have done or should have done. 
2. I feel quite guilty most of the time. 
3. I feel guilty all of the time. 
6. Punishment Feelings 
0. I don't feel I am being punished. 
1. I feel I may be punished. 
2. I expect to be punished. 
3. I feel I am being punished. 
7. Self-Dislike 
0. I feel the same about myself as ever. 
1. I have lost confidence in myself. 






3. I dislike myself.  
8. Self-Criticalness 
0. I don't criticize or blame myself more than usual. 
1. I am more critical of myself than I used to be. 
2. I criticize myself for all of my faults. 
3. I blame myself for everything bad that happens. 
9. Suicidal Thoughts or Wishes 
0. I don't have any thoughts of killing myself. 
1. I have thoughts of killing myself, but I would not carry them out. 
2. I would like to kill myself. 
3. I would kill myself if I had the chance. 
10. Crying 
0. I don't cry any more than I used to. 
1. I cry more than I used to. 
2. I cry over every little thing. 
3. I feel like crying, but I can't. 
11. Agitation 
0. I am no more restless or wound up than usual. 
1. I feel more restless or wound up than usual. 
2. I am so restless or agitated, it's hard to stay still. 
3. I am so restless or agitated that I have to keep moving or doing something. 
12. Loss of Interest 
0. I have not lost interest in other people or activities. 
1. I am less interested in other people or things than before. 
2. I have lost most of my interest in other people or things. 
3. It's hard to get interested in anything. 
13. Indecisiveness 
0. I make decisions about as well as ever. 
1. I find it more difficult to make decisions than usual. 
2. I have much greater difficulty in making decisions than I used to. 
3. I have trouble making any decisions. 
14. Worthlessness 
0. I do not feel I am worthless. 
1. I don't consider myself as worthwhile and useful as I used to. 
2. I feel more worthless as compared to others. 
3. I feel utterly worthless. 
15. Loss of Energy 
0. I have as much energy as ever. 
1. I have less energy than I used to have. 
2. I don't have enough energy to do very much. 
3. I don't have enough energy to do anything.  
16. Changes in Sleeping Pattern 
0. I have not experienced any change in my sleeping. 
1a I sleep somewhat more than usual. 
1b I sleep somewhat less than usual. 






2b I sleep a lot less than usual. 
3a I sleep most of the day. 
3b I wake up 1-2 hours early and can't get back to sleep. 
17. Irritability 
0. I am not more irritable than usual. 
1. I am more irritable than usual. 
2. I am much more irritable than usual. 
3. I am irritable all the time. 
18. Changes in Appetite 
0. I have not experienced any change in my appetite. 
1a My appetite is somewhat less than usual. 
1b My appetite is somewhat greater than usual. 
2a My appetite is much less than before. 
2b My appetite is much greater than usual. 
3a I have no appetite at all. 
3b I crave food all the time. 
19. Concentration Difficulty 
0. I can concentrate as well as ever. 
1. I can't concentrate as well as usual. 
2. It's hard to keep my mind on anything for very long. 
3. I find I can't concentrate on anything. 
20. Tiredness or Fatigue 
0. I am no more tired or fatigued than usual. 
1. I get more tired or fatigued more easily than usual. 
2. I am too tired or fatigued to do a lot of the things I used to do. 
3. I am too tired or fatigued to do most of the things I used to do. 
21. Loss of Interest in Sex 
0. I have not noticed any recent change in my interest in sex. 
1. I am less interested in sex than I used to be. 
2. I am much less interested in sex now. 
3. I have lost interest in sex completely. 
 










Form 7. Charleston Psychiatric Outpatient Satisfaction Scale  
 
Your opinions about us are very important. Please give your honest opinions on each question.  
 
Please rate each item on the following scale: EXCELLENT, VERY GOOD, GOOD, FAIR, or 




Excellent Good Fair Poor Does Not 
Apply 
1. Helpfulness of the secretary       5 4 3 2 1 N/A 
2. Information provided about payment for 
services 
5 4 3 2 1 N/A 
3. Amount of time waiting to be seen 5 4 3 2 1 N/A 
4. Amount of information given to you about 
your problem 
5 4 3 2 1 N/A 
5. Respect shown for your opinions about 
treatment 
5 4 3 2 1 N/A 
6. Matching of treatment plan to your individual 
needs 
5 4 3 2 1 N/A 
7. Helpfulness of the services you have received 5 4 3 2 1 N/A 
8. Overall quality of care provided 5 4 3 2 1 N/A 
9. Appearance of the waiting room 5 4 3 2 1 N/A 
10. Appearance of the office 5 4 3 2 1 N/A 
11. Office hours 5 4 3 2 1 N/A 
12. Location of this outpatient service 5 4 3 2 1 N/A 
13. Parking 5 4 3 2 1 N/A 
14. Clear and correct monthly bill 5 4 3 2 1 N/A 
15. Would you recommend this program to a 
friend or family member? (circle one) 
Yes              No             Probably            Definitely     
      Probably Not                       Definitely Not 
How could we improve our services?  
Other Comments: 
       
Scoring the Charleston Psychiatric Outpatient Satisfaction Scale Items 1 through 14 are scored 
using the following 5-point scale: 5 = Excellent 4 = Very good 3 = Good 2 = Fair 1 = Poor  
 
Item 15 is scored using the following 4-point scale. 4 = Yes, definitely 3 = Yes, probably 2 = No, 
probably not 1 = No, definitely not  
 
The scale is scored by summing the scores of all individual items except the anchor items (items 
8 and 15). The possible range is 13 to 65.  
 
Copyright notice: The Charleston Psychiatric Outpatient Satisfaction Scale is copyrighted by Bartley C. Frueh, Ph.D. Permission has been 






uses of the scale, the owner of the copyright should be contacted. Citation: Pellegrin KL, Stuart GW, Maree B, Frueh BC, Ballenger JC. A brief 




Form 8. Sample Size Calculation 
 
Our sample size was calculated using the GLIMMPSE software created by University of 
Colorado for sample size calculations for mixed effects models.1 Using a power of .80 and a type 
1 error rate of 0.1, a total sample size of 226 was recommended (113 each in treatment and 
control groups). The key assumption for this calculation was that over the course of the study 
telepsychiatry patients’ improvements would be superior to face-to-face treatment by the 
minimal clinically significant amount (5 points on the 60-point scale2). Furthermore, we assumed 
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